오하이오의 백혈병 임상 시험
백혈병 관련 연구 26개가 오하이오 내 여러 지역에서 참여자를 모집하고 있습니다.
오하이오의 도시
공식 연구 텍스트(영어)
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Quetzal Site 8, Columbus
피험자 모집 중3상
18세 ~ 71세 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT07504458A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Ohio State University, Columbus
피험자 모집 중1/2상
30 Days · 모든 성별 · 2026. 9. 16. 업데이트됨 · NCT04065399Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Cleveland
피험자 모집 중3상
18세 ~ 18세 · 모든 성별 · 2026. 9. 8. 업데이트됨 · NCT07509151Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
- Ohio State University Comprehensive Cancer Center, Columbus
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 2. 업데이트됨 · NCT07249346Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
- Cinn Children Hosp Medical Center, Cincinnati
피험자 모집 중2상
1세 ~ 18세 · 모든 성별 · 2026. 9. 2. 업데이트됨 · NCT07354074First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
- Cincinnati Children's Hospital Medical Center, Cincinnati
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 1. 업데이트됨 · NCT07586618Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- UH Seidman Cancer Center, Cleveland
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 20. 업데이트됨 · NCT06001788Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Ohio State University, Columbus
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 20. 업데이트됨 · NCT07007312Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Cincinnati Children's Hospital Medical Center, Cincinnati
피험자 모집 중2상
7세 ~ 25세 · 모든 성별 · 2026. 8. 19. 업데이트됨 · NCT05082519Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- The Ohio State University Wexner Medical Center, Columbus
피험자 모집 중1/2상
13세 ~ 90세 · 모든 성별 · 2026. 8. 6. 업데이트됨 · NCT06533579Hairy Cell Leukemia Patient Data Registry
- Ohio State University Comprehensive Cancer Center, Columbus
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 7. 2. 업데이트됨 · NCT02560883Integrated Cancer Repository for Cancer Research
- Aultman Alliance Community Hospital, Alliance
- Aultman Hospital, Canton
피험자 모집 중관찰 연구건강한 지원자 환영
19세 ~ 110세 · 모든 성별 · 2026. 6. 29. 업데이트됨 · NCT02012699A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Columbus
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 6. 17. 업데이트됨 · NCT05475925Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Cincinnati Children's Hospital Medical Center, Cincinnati
피험자 모집 중관찰 연구
0세 ~ 38세 · 모든 성별 · 2026. 6. 4. 업데이트됨 · NCT06131801Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2026. 5. 18. 업데이트됨 · NCT01790152A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 4. 30. 업데이트됨 · NCT04256317Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 4. 15. 업데이트됨 · NCT07356245The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Gabrail Cancer Center Research,, Canton
피험자 모집 중1/2상
12세 ~ 95세 · 모든 성별 · 2026. 4. 15. 업데이트됨 · NCT04329728Shwachman Diamond Syndrome Registry and Study
- Cincinnati Children's Hospital Medical Center, Cincinnati
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2026. 4. 6. 업데이트됨 · NCT06056908A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University Hospitals Cleveland Medical Center, Cleveland
- Cleveland Clinic Taussig Cancer Institute, Cleveland
- The James Cancer Hospital and Solove Research Institute, Columbus
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 3. 13. 업데이트됨 · NCT05735184Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- Cincinnati Children's Hospital Medical Center, Cincinnati
피험자 모집 중1상
1세 ~ 39세 · 모든 성별 · 2026. 2. 18. 업데이트됨 · NCT03826992cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Cleveland Clinic, Cleveland
피험자 모집 중관찰 연구건강한 지원자 환영
40세 이상 · 모든 성별 · 2026. 1. 20. 업데이트됨 · NCT05366881Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Gabrail Cancer Research Center, Canton
피험자 모집 중1상
18세 이상 · 모든 성별 · 2025. 10. 31. 업데이트됨 · NCT06549790SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2025. 10. 28. 업데이트됨 · NCT03452774A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- The Ohio State University Wexner Medical Center - James Cancer Hosp, Columbus
피험자 모집 중1상
18세 이상 · 모든 성별 · 2025. 9. 24. 업데이트됨 · NCT06501196Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- University of Cincinnati, Cincinnati
피험자 모집 중1상
18세 이상 · 모든 성별 · 2024. 11. 15. 업데이트됨 · NCT06034275ClinicalTrials.gov 출처, 2026. 9. 30. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.